Analysts Conflictied on These Healthcare Names: Kindred Healthcare (NYSE: KND), Accelerate Diagnostics (NASDAQ: AXDX) and Coherus Biosciences (NASDAQ: CHRS)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kindred Healthcare (NYSE: KND), Accelerate Diagnostics (NASDAQ: AXDX) and Coherus Biosciences (NASDAQ: CHRS).

Kindred Healthcare (NYSE: KND)

J.P. Morgan analyst Gary Taylor reiterated a Hold rating on Kindred Healthcare (NYSE: KND) yesterday and set a price target of $11. The company’s shares opened today at $6.25, close to its 52-week low of $5.65.

According to TipRanks.com, Taylor is a 4-star analyst with an average return of 13.9% and a 67.9% success rate. Taylor covers the Healthcare sector, focusing on stocks such as Quest Diagnostics Inc., WellCare Health Plans, and Genesis Healthcare.

Currently, the analyst consensus on Kindred Healthcare is Hold and the average price target is $10, representing a 60.0% upside.

In a report released today, RBC Capital also downgraded the stock to Hold with a $9 price target.
Accelerate Diagnostics (NASDAQ: AXDX)

In a report released yesterday, Tycho Peterson from J.P. Morgan reiterated a Buy rating on Accelerate Diagnostics (NASDAQ: AXDX), with a price target of $25. The company’s shares opened today at $24.15.

According to TipRanks.com, Peterson is a 5-star analyst with an average return of 13.0% and a 63.8% success rate. Peterson covers the Healthcare sector, focusing on stocks such as Dentsply International Inc., Albany Molecular Research, and Quintiles Transnational.

Accelerate Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $25.

Coherus Biosciences (NASDAQ: CHRS)

J.P. Morgan analyst Chris Schott reiterated a Buy rating on Coherus Biosciences (NASDAQ: CHRS) yesterday and set a price target of $38. The company’s shares opened today at $26.25.

Schott said:

“This afternoon, Coherus reported 3Q16 results with focus remaining on the USPTO rejected the company’s IPR on Humira ‘166 formulation patent. We continue to see greater uncertainty around a 2018 launch of CHRS’s biosimilar Humira following this week’s announcement but will watch to see if Coherus’s new formulations of the product could allow the company to circumvent ‘166 and still launch in the 2018 timeframe.”

According to TipRanks.com, Schott is a 1-star analyst with an average return of -2.4% and a 42.0% success rate. Schott covers the Healthcare sector, focusing on stocks such as Endo International, Impax Laboratories, and Merck & Company.

Currently, the analyst consensus on Coherus Biosciences is Strong Buy and the average price target is $46, representing a 75.2% upside.

In a report issued on November 7, Citigroup also maintained a Buy rating on the stock with a $36 price target.